PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 3061383-0 1988 In vitro activity of mecillinam and amoxicillin/clavulanic acid against strains of Escherichia coli producing TEM-1, Oxa-1 and chromosomal beta-lactamases. Amdinocillin 21-31 hypothetical protein Escherichia coli 110-115 1389936-8 1992 The mean half-life of elimination after parenteral administration of mecillinam was significantly longer during both early (t1/2,Z = 133 +/- 38 min, P less than 0.05) and late pregnancy (t1/2,Z = 107 +/- 41 min, P less than 0.05) as compared with the non-pregnant state (t1/2,Z = 75 +/- 21 min). Amdinocillin 69-79 CD6 molecule Homo sapiens 271-282 3061383-0 1988 In vitro activity of mecillinam and amoxicillin/clavulanic acid against strains of Escherichia coli producing TEM-1, Oxa-1 and chromosomal beta-lactamases. Amdinocillin 21-31 beta-lactamase OXA-1 precursor Escherichia coli 117-122 3061383-5 1988 Strains producing Oxa-1 and chromosomal beta-lactamases usually where highly susceptible to mecillinam but only moderately sensitive or resistant to the combination of amoxicillin/clavulanic acid. Amdinocillin 92-102 beta-lactamase OXA-1 precursor Escherichia coli 18-23 3061383-1 1988 The in vitro activity of mecillinam and amoxicillin/clavulanic acid against Escherichia coli strains producing beta-lactamases of the TEM-1, Oxa-1 and chromosomal type were studied using the broth and agar dilution technique. Amdinocillin 25-35 hypothetical protein Escherichia coli 134-139 3061383-6 1988 In vitro activity of TEM-1 E. coli to mecillinam was strongly reduced when tested in a broth dilution technique. Amdinocillin 38-48 hypothetical protein Escherichia coli 21-26 3061383-1 1988 The in vitro activity of mecillinam and amoxicillin/clavulanic acid against Escherichia coli strains producing beta-lactamases of the TEM-1, Oxa-1 and chromosomal type were studied using the broth and agar dilution technique. Amdinocillin 25-35 beta-lactamase OXA-1 precursor Escherichia coli 141-146 3061383-4 1988 Both, mecillinam and amoxicillin/clavulanic acid were considerably more active against TEM-1 strains than ampicillin alone, but, with increasing specific beta-lactamase activity, a decrease of susceptibility was found. Amdinocillin 6-16 hypothetical protein Escherichia coli 87-92 6323378-0 1984 Pivmecillinam, co-trimoxazole and oral mecillinam in gastroenteritis due to Vibrio spp. Amdinocillin 3-13 histocompatibility minor 13 Homo sapiens 83-86 6323378-5 1984 Pivmecillinam and oral mecillinam appeared to be of equal value in a further 22 adults infected by Vibrio spp. Amdinocillin 3-13 histocompatibility minor 13 Homo sapiens 106-109 31243859-4 2019 Pivmecillinam (prodrug of mecillinam), an oral antimicrobial agent is effective against ESBL producing organisms. Amdinocillin 3-13 EsbL Escherichia coli 88-92 408321-1 1977 In vitro studies carried out in this Department confirmed the high activity of mecillinam against Salmonella spp. Amdinocillin 79-89 histocompatibility minor 13 Homo sapiens 109-112 32868328-2 2020 CTX-M-215 differed from CTX-M-125, a CTX-M-ESBL by an N132D substitution, which decreased the hydrolytic activities towards penicillins and cephalosporins except for mecillinam. Amdinocillin 166-176 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 0-3 31596663-4 2020 The mecillinam MIC50/MIC90 results dropped to 1/4 mg/L (from 128/>256 mg/L when tested alone) against metallo-beta-lactamase (MBL)-producing E. coli. Amdinocillin 4-14 NDM-1 Escherichia coli 102-124 32120467-8 2019 ABST of ESBL producers revealed high resistance rates for quinolones (41%) and >80% sensitivity for nitrofurantoin, fosfomycin, mecillinam, aminoglycosides and carbapenems. Amdinocillin 136-146 EsbL Escherichia coli 8-12 32120467-12 2019 >80% ESBL organisms show high sensitivity for aminoglycosides, carbapenems, nitrofurantoin, mecillinam and fosfomycin. Amdinocillin 100-110 EsbL Escherichia coli 5-9 31573735-0 2019 Mutational change of CTX-M-15 to CTX-M-127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient. Amdinocillin 56-66 hypothetical protein Escherichia coli 21-29 31243859-5 2019 We analysed the sensitivity rates of ESBL-producing Enterobacteriaceae from urine samples to mecillinam and to document if pivmecillinam is a suitable alternative option in the treatment of UTI. Amdinocillin 93-103 EsbL Escherichia coli 37-41 31243859-12 2019 Overall 95% (935/986 isolates) of ESBL-producing urinary isolates were sensitive to mecillinam. Amdinocillin 84-94 EsbL Escherichia coli 34-38 31243859-16 2019 More studies on in vitro activity of mecillinam against ESBL producing organism and its use and clinical outcome should be tried in future. Amdinocillin 37-47 EsbL Escherichia coli 56-60 30917983-4 2019 Among extended-spectrum beta-lactamase (ESBL) producers, 95.2% (99/104) were mecillinam susceptible, including two OXA-48-producing Klebsiella pneumoniae isolates. Amdinocillin 77-87 CTX-M-15 Klebsiella pneumoniae 6-38 28369441-0 2017 A combination of mecillinam and amoxicillin/clavulanate can restore susceptibility of high-level TEM-1-producing Escherichia coli to mecillinam. Amdinocillin 17-27 hypothetical protein Escherichia coli 97-102 30236958-0 2019 Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli in 24-h time-kill experiments. Amdinocillin 43-53 beta-lactamase Escherichia coli 126-140 30236958-1 2019 This study aimed to evaluate the potential synergistic and bactericidal effects of mecillinam in combination with amoxicillin and clavulanic acid against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. Amdinocillin 83-93 EsbL Escherichia coli 154-186 28369441-0 2017 A combination of mecillinam and amoxicillin/clavulanate can restore susceptibility of high-level TEM-1-producing Escherichia coli to mecillinam. Amdinocillin 133-143 hypothetical protein Escherichia coli 97-102 28369441-5 2017 Results: We showed that the presence of an SNP in the promoter of the plasmidic TEM-1 beta-lactamase gene is sufficient to confer resistance to mecillinam. Amdinocillin 144-154 TEM-1 beta-lactamase Escherichia coli 80-100 11952728-0 2002 Mecillinam susceptibility as an indicator of beta-lactamase production in Staphylococcus aureus. Amdinocillin 0-10 beta-lactamase Staphylococcus aureus 45-59 24454943-0 2014 High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli. Amdinocillin 22-32 EsbL Escherichia coli 108-112 24454943-1 2014 A population-based study was performed to investigate the efficacy of mecillinam treatment of community-acquired urinary tract infections (CA-UTI) caused by extended-spectrum beta-lactamase (ESBL) producing Escherichia coli. Amdinocillin 70-80 EsbL Escherichia coli 191-195 24454943-8 2014 Mecillinam treatment failure was observed in 18 (44%) of patients infected by ESBL-producing strains and in 16 (14%) of patients with a CA-UTI caused by ESBL non-producing strains. Amdinocillin 0-10 EsbL Escherichia coli 78-82 24454943-8 2014 Mecillinam treatment failure was observed in 18 (44%) of patients infected by ESBL-producing strains and in 16 (14%) of patients with a CA-UTI caused by ESBL non-producing strains. Amdinocillin 0-10 EsbL Escherichia coli 153-157 24454943-9 2014 Multivariable analysis showed that ESBL status (odds ratio (OR) 3.2, 95% confidence interval (CI) 1.3-7.8, p = 0.009) and increased MIC of mecillinam (OR 2.0 for each doubling value of MIC, CI 1.4-3.0, p<0.001) were independently associated with mecillinam treatment failure. Amdinocillin 249-259 EsbL Escherichia coli 35-39 17289762-7 2007 Both wild-type and truncated, soluble forms of PBP 2 were shown to bind penicillins and a competition assay demonstrated their specificity for mecillinam. Amdinocillin 143-153 penicillin-binding protein 2 Pseudomonas aeruginosa PAO1 47-52 24454943-10 2014 This study showed a high rate of mecillinam treatment failure in CA-UTIs caused by ESBL producing E. coli. Amdinocillin 33-43 EsbL Escherichia coli 83-87 24454943-12 2014 Further studies addressing the use of mecillinam against ESBL-producing E. coli, with emphasis on optimal dosing and combination therapy with beta-lactamase inhibitors, are warranted. Amdinocillin 38-48 EsbL Escherichia coli 57-61 11952728-1 2002 The use of direct susceptibility testing from specimens has led to the fortuitous observation that penicillin-susceptible strains have larger inhibition zones for mecillinam than do beta-lactamase producers. Amdinocillin 163-173 beta-lactamase Staphylococcus aureus 182-196 11952728-7 2002 In conclusion, the size of the mecillinam inhibition zone is found to be a useful supplementary test in the clinically important distinction between beta-lactamase-producing and non-producing isolates of S. aureus. Amdinocillin 31-41 beta-lactamase Staphylococcus aureus 149-163 11051618-1 2000 The activity of mecillinam, a beta-lactam antibiotic with high affinity for gram-negative penicillin-binding protein 2 (PBP2), was assessed against ampicillin-resistant Escherichia coli strains producing beta-lactamases representing the three molecular classes, A (TEM-1 and -3, SHV-3 and IRT-5), C (AmpC) and D (OXA-3). Amdinocillin 16-26 hypothetical protein Escherichia coli 265-284 10969046-1 2000 The activity of mecillinam, a beta-lactam antibiotic with high affinity for Gram-negative penicillin-binding protein 2 (PBP2), was assessed against ampicillin-resistant Escherichia coli strains producing beta-lactamases representing the three molecular classes, A (TEM-1 and -3, SHV-3 and IRT-5), C (AmpC) and D (OXA-3). Amdinocillin 16-26 hypothetical protein Escherichia coli 265-284